No tomar el medicamento si hay antecedentes personales o familiares de neoplasia endocrina mltiple tipo 2 (causa tumores en las glndulas endocrinas)
seek urgent advice for persistent abdominal pain, palpitations, hypoglycaemia symptoms, or injection site infection
Protein requirements on semaglutide are covered in a dedicated guide
Not every patient with excess weight is an appropriate candidate for GLP-1 therapy
Acknowledgements We thank the participants whose data contributed to this study, as well as Niels Rode Kristensen, PhD (Novo Nordisk A/S, Sborg, Denmark) for taking part in the planning of the analysis
The mechanism differs between product types, but in both cases the end result is a reduction in fat cell volume followed by clearance of the resulting material through the bodys lymphatic system